NCT02409316
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes: Must have ER+ tumor(s)
Exclusions: Patients with a history of HER2+ breast cancer
https://ClinicalTrials.gov/show/NCT02409316